FISCHER

Fischer Medical Ventures Share Price

 

 

Start SIP in FISCHER

Start SIP

Performance

  • Low
  • ₹59
  • High
  • ₹59
  • 52 Week Low
  • ₹59
  • 52 Week High
  • ₹125
  • Open Price₹59
  • Previous Close₹65
  • Volume448,658

Investment Returns

  • Over 1 Month -37.38%
  • Over 3 Month -41.13%
  • Over 6 Month -30.99%
  • Over 1 Year -6.01%

Smart Investing Starts Here Start SIP with Fischer Medical Ventures for Steady Growth!

Invest Now

Fischer Medical Ventures Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 191.4
  • PEG Ratio
  • -
  • Market Cap Cr
  • 3,813
  • P/B Ratio
  • 12.4
  • Average True Range
  • 7.92
  • EPS
  • 0.31
  • Dividend Yield
  • 0
  • MACD Signal
  • -4.18
  • RSI
  • 21.24
  • MFI
  • 47.06

Fischer Medical Ventures Financials

Fischer Medical Ventures Technicals

EMA & SMA

Current Price
₹58.80
-6.5 (-9.95%)
  • Bearish Moving Average 0
  • Bullish Moving Average 0
  • 20 Day
  • ₹90.95
  • 50 Day
  • ₹97.86
  • 100 Day
  • ₹96.90
  • 200 Day
  • ₹89.88

Resistance and Support

58.8 Pivot Speed
  • R3 58.80
  • R2 58.80
  • R1 58.80
  • S1 58.80
  • S2 58.80
  • S3 58.80

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Fischer Medical Ventures Ltd has an operating revenue of Rs. 170.67 Cr. on a trailing 12-month basis. An annual revenue growth of 422% is outstanding, Pre-tax margin of 2% needs improvement, ROE of 0% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 76 which is a FAIR score but needs to improve its earnings, a RS Rating of 16 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 118 indicates it belongs to a poor industry group of Chemicals-Specialty and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Fischer Medical Ventures Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-10-28 Quarterly Results & Others To consider other business matters split from Rs. 10/- to Re. 1/-.
2025-08-14 Quarterly Results & A.G.M.
2025-07-28 Stock Split
2025-05-28 Audited Results & Final Dividend
2025-03-26 Others Inter-alia, to consider 1. Appointment of Ms. Jaya Ankur Singhania as Independent Director. 2. Notice of Postal Ballot with explanatory statements and other related matter. 3. Other business matters. split from Rs. 10/- to Re. 1/-.
Date Purpose Remarks
2025-09-12 Split Rs.0.00 split from Rs. 10/- to Re. 1/-.

Fischer Medical Ventures F&O

Fischer Medical Ventures Shareholding Pattern

61.8%
0%
5.57%
26.29%
6.34%

About Fischer Medical Ventures

  • NSE Symbol
  • FISCHER
  • BSE Symbol
  • 524743
  • Chairman & Managing Director
  • Mr. Ravindran Govindan
  • ISIN
  • INE771F01041

Similar Stocks to Fischer Medical Ventures

Fischer Medical Ventures FAQs

Fischer Medical Ventures share price is ₹58 As on 16 November, 2025 | 03:13

The Market Cap of Fischer Medical Ventures is ₹3813.3 Cr As on 16 November, 2025 | 03:13

The P/E ratio of Fischer Medical Ventures is 191.4 As on 16 November, 2025 | 03:13

The PB ratio of Fischer Medical Ventures is 12.4 As on 16 November, 2025 | 03:13

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23